Price:
Rs. 100,000.00
Sample Type: Tissue
Fasting Not Required
Notes:N8225
Frequently Asked Questions (FAQ's):
What does the GeneCore Paradigm Comprehensive 22C3 Panel at Metropolis Healthcare include?
It analyzes multiple cancer-related genes and evaluates PD-L1 expression using the 22C3 clone for therapy decision-making.
How does Metropolis Healthcare perform this comprehensive panel?
Metropolis Healthcare uses deep NGS for genomic profiling and validated 22C3 immunohistochemistry for PD-L1 assessment.
Who should consider taking this test at Metropolis Healthcare?
Patients with solid tumors who need detailed molecular insights or immunotherapy eligibility evaluation should consider this panel.
Is fasting required for this test at Metropolis Healthcare?
No fasting is required; the test is performed on tumor tissue samples provided by the clinician.
How long do results take at Metropolis Healthcare?
Results usually take 2–3 weeks due to extensive sequencing and PD-L1 22C3 evaluation.
Can this panel at Metropolis Healthcare help guide immunotherapy decisions?
Yes, PD-L1 22C3 scoring helps determine suitability for immune checkpoint inhibitor therapies.
How accurate is PD-L1 testing and genomic analysis at Metropolis Healthcare?
Metropolis Healthcare ensures high accuracy through validated IHC methods and stringent NGS quality controls.
Does this panel support long-term cancer treatment planning at Metropolis Healthcare?
Yes, the combined genomic and immunotherapy insights help clinicians design personalized, long-term management strategies.